REPLIGEN CORP acquired Avitide, Inc. for ~$150 million ($75M cash + $75M in Repligen stock), a transaction completed in September 2021, structured as combination (cash plus stock).
Avitide, Inc. operates in Proteins / Chromatography, is based in Lebanon, New Hampshire, USA, had revenue of about ~$10 million projected 2022 revenue. Acquisition of privately held Avitide, Inc., a market leader in affinity ligand discovery and development, moving Repligen into affinity resin solutions for gene therapy and other emerging modalities. The deal strengthened Repligen's Proteins business and complemented its established partnership with Navigo GmbH. Avitide was expected to contribute ~$10 million in revenue in 2022.
Hunt said 'the addition of Avitide is a major step forward in building out our Proteins business and in particular our affinity ligand discovery engine,' building off the partnership with Navigo GmbH.
Affinity ligand discovery platform addressing high-growth new-modality purification. Complements Navigo partnership; extends Proteins franchise into affinity resins. Repligen Proteins franchise
The addition of Avitide is a major step forward in building out our Proteins business and in particular our affinity ligand discovery engine. This acquisition builds off the excellent partnership we have already established with Navigo GmbH and really strengthens and expands our ligand discovery and development capabilities.Tony J. Hunt, President and CEO, Repligen
We have made tremendous progress in affinity ligand and chromatography development over the past decade. Repligen is the ideal partner to drive the expanded development of affinity resins for gene therapy and other emerging modalities.Kevin Isett, President and CEO, Avitide
Advisory firms were not disclosed for this transaction.